Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 55Biopsy 43pembrolizumab 25Carboplatin 25Radiation 24Radiotherapy 23Cyclophosphamide 23Nivolumab 21Paclitaxel 20Cisplatin 20olaparib 18Etoposide 18Doxorubicin 17X-Rays 16Vincristine 16Taxes 15Immunoglobulin G 15Disulfides 15Radiotherapy, Intensity-Modulated 14Leucovorin 14Dexamethasone 14Cytarabine 14Bevacizumab 14durvalumab 13Prednisone 13Platinum 131,2-diaminocyclohexaneplatinum II citrate 13Methotrexate 11Ipilimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × isatuximab × 30 days × Clear all
NCT04430894 2026-06-03

KRDI in Transplant-Eligible MM

Massachusetts General Hospital

Phase 2 Active not recruiting
50 enrolled 20 charts
Plasma cell

Multiple Myeloma

NCT05911321 2026-05-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
6 enrolled 5 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡